Best of ASCO - 2014 Annual Meeting

 

Welcome

Biomarkers/Epidemiology/Outcomes

Melanoma/Skin Cancers

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
obesity and metastatic melanoma: A national perspective from the pre-immune checkpoint inhibitor era.

Aakash Desai

e21032

Anal melanoma: A comparative comprehensive genomic profiling study.

Jeffrey S. Ross

9566

Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.

Amit Hemadri

9579

Association of baseline neutrophil-to-lymphocyte ratio (NLR) with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.

Amit Hemadri

9571

Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.

Amit Hemadri

9572

Circulating PD-L1-exosomes to monitor tumor response in melanoma patients.

Charlee Nardin

9517

Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets).

Jenny HJ Lee

9581

Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM).

Daniel Ying Wang

9564

Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM).

Claus Garbe

9518

Comprehensive genomic profiling reveals distinct patterns of driver mutations and chromosomal alterations in acral and mucosal melanomas.

Zhengyun Zou

9576

Consensus gene expression analysis to identify key hallmarks of cancer in malignant melanoma.

Emma O'Connor

e21045

Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.

Khashayar Esfahani

9561

Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition.

Lucas Basler

9575

Disparities in the occurrence of late effects following treatment among adolescent and young adult melanoma survivors.

Alicia Gingrich

9580

Does the initial biopsy type affect clinically important outcomes in malignant melanoma? A meta-analysis.

Fatima Fayyaz

e21041

Impact of body composition on outcomes from anti-programmed death-1 (PD-1) treatment.

Arissa Young

9516

Integrative molecular analysis of metastatic Merkel cell carcinoma to identify predictive biomarkers of response to avelumab.

Sara Georges

9569

Markers of melanoma progression in the blood serum structure.

Alla I. Shikhlyarova

e21035

Molecular profiling of melanoma brain metastases (MBM) compared to primary cutaneous melanoma (CM).

Gino Kim In

9565

Mutation landscape of Chinese melanoma patients.

Fuxue Huang

9563

Neutrophil to Lymphocyte ratio (NLR): A prognostic marker in melanoma patients receiving immunotherapy.

Richard Thomas O'Dwyer

9573

Outcomes in MAGE+ cutaneous squamous cell carcinoma with perineural invasion treated with surgery followed by postoperative radiation therapy.

Mary Stevenson

e21043

Outcomes of melanoma soft parts/clear cell sarcoma (MSP/CCS) patients (pts) with immune and targeted therapies.

Amy Little Jones

e21046

Patterns of major surgeries among patients diagnosed with cutaneous squamous cell carcinoma (CSCC).

Chieh-I Chen

e21034

Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma.

Michael C. Lowe

TPS9603

Plasma proteomic analyses and treatment predictive biomarker candidates in melanoma patients receiving immune checkpoint blockade or targeted therapy.

Hanna Eriksson

9574

Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.

Eric Robinson

9577

Pretreatment steroid use and completion of immunotherapy: A population-based study.

Grace L. Lu-Yao

9567

Prognostic differences and the effect of radiotherapy on survival in Merkel cell carcinoma: A retrospective analysis of a Swedish cohort.

Hannah Bjorn-Andtback

e21047

Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI).

Fiona Taylor

9568

Quantitative assessment of tumor-infiltrating neutrophils to predict immunotherapy responses in metastatic melanoma.

Jesus Vera Aguilera

e21039

Real-world outcomes of advanced melanoma patients treated with pembrolizumab who have failed prior lines of therapy.

Wanmei Ou

e21031

Response to PD-1 inhibition in early- and late-relapsing cutaneous melanoma.

Kelly Fitzgerald

e21038

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.

Jeffrey S. Weber

100

Specificity of markers CD44 and S100 for skin melanoma and nevi tissues.

Irina A. Goroshinskaya

e21036

Sustainable responses in metastatic melanoma patients with/without brain metastases after immunotherapy induced CR.

Florentia Dimitriou

e21042

The clinical utility of neuron-specific enolase serum levels as a biomarker for Merkel cell carcinoma.

Linde M. van Veenendaal

9570

The relationship between obesity and immunotherapy: It's complicated.

Douglas MacArthur Donnelly

9562

The solved and unresolved issues of melanoma staging: A comparison of American Joint Committee on Cancer (AJCC) 7th versus 8th edition.

Shirin Bajaj

9578

Three-year survival outcomes in a prospective cohort evaluating a prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma (CM).

Eddy C. Hsueh

9519

Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting.

C. Lance Cowey

e21033

Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma.

Bixia Tang

e21050

What impact do the proton pump inhibitors have on the efficacy of immune check point inhibitors in metastatic malignant melanoma?

Muhammad Zubair Afzal

e21040